Pancreatic Cancer Research

ResearcherHudson Institute of Medical ResearchActive in the last 2 years

Brendan John Jenkins

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7552-4656; OpenAlex author ID A5055490340. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
32
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 4 papers · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 2 papers

Papers 11

  1. Cancer cell-intrinsic inflammasome protein ASC links innate immunity with mitochondrial metabolism in driving pancreatic cancer. Last author DOI 10.1038/s41467-026-69398-w↗
  2. Endoscopic ultrasound molecular evaluation of pancreatic cancer trial to profile molecular landscape of inoperable pancreatic ductal adenocarcinoma. Co-author DOI 10.1055/a-2733-1068↗
  3. Circulating Tumor DNA Is an Accurate Diagnostic Tool and Strong Prognostic Marker in Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002239↗
  4. KRAS G12D Mutation Subtype in Pancreatic Ductal Adenocarcinoma: Does It Influence Prognosis or Stage of Disease at Presentation? Co-author DOI 10.3390/cells11193175↗
  5. TLR2 activation promotes tumour growth and associates with patient survival and chemotherapy response in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41388-021-01992-2↗
  6. Targeted Transcriptome and KRAS Mutation Analysis Improve the Diagnostic Performance of EUS-FNA Biopsies in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-21-1107↗
  7. EUS-FNA Biopsies to Guide Precision Medicine in Pancreatic Cancer: Results of a Pilot Study to Identify KRAS Wild-Type Tumours for Targeted Therapy. Co-author DOI 10.3389/fonc.2021.770022↗
  8. The EUS molecular evaluation of pancreatic cancer: A prospective multicenter cohort trial. Last author DOI 10.4103/eus-d-20-00230↗
  9. Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers12123816↗
  10. Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer. Last author DOI 10.3390/cancers10020035↗
  11. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors. Co-author DOI 10.1002/ijc.30648↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniel Gerald Croagh · 11 shared papers, 2017–2026 · strength 1.65
  2. Joanne Lundy · 10 shared papers, 2018–2026 · strength 1.57
  3. John Raymond Zalcberg · 3 shared papers, 2021–2026 · strength 0.45
  4. Marion Harris · 3 shared papers, 2021–2022 · strength 0.39
  5. William Berry · 3 shared papers, 2017–2021 · strength 0.35
  6. Belinda Lee · 2 shared papers, 2021–2026 · strength 0.33
  7. Manoop S. Bhutani · 2 shared papers, 2021–2026 · strength 0.33
  8. Rav Sellahewa · 1 shared paper, 2023 · strength 0.24
  9. Owen McKay · 1 shared paper, 2026 · strength 0.23
  10. Sean Michael Grimmond · 1 shared paper, 2026 · strength 0.23
  11. Yu Chinn Joshua Chey · 1 shared paper, 2026 · strength 0.23
  12. David Herrmann · 1 shared paper, 2026 · strength 0.23
  13. Brooke Pereira · 1 shared paper, 2026 · strength 0.23
  14. Paul Timpson · 1 shared paper, 2026 · strength 0.23
  15. Henry Shen · 1 shared paper, 2022 · strength 0.16
  16. David Goldstein · 1 shared paper, 2021 · strength 0.12
  17. Val Gebski · 1 shared paper, 2021 · strength 0.12
  18. Marina Pajic · 1 shared paper, 2021 · strength 0.12
  19. Eva Segelov · 1 shared paper, 2021 · strength 0.10
  20. Charles H. C. Pilgrim · 1 shared paper, 2021 · strength 0.10
  21. Rhys Vaughan · 1 shared paper, 2021 · strength 0.10
  22. Rachna T. Shroff · 1 shared paper, 2020 · strength 0.09
  23. Nina G. Steele · 1 shared paper, 2020 · strength 0.09
  24. Jayati L. Chakrabarti · 1 shared paper, 2020 · strength 0.09
  25. Pritha Adhikary · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.